{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:47:12Z","timestamp":1782398832603,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004823","name":"Nagoya University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004823","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Today"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00595-025-03223-7","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:19:25Z","timestamp":1770020365000},"page":"1320-1329","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of conversion surgery for patients with locally advanced pancreatic cancer under strict indication criteria"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6362-2243","authenticated-orcid":false,"given":"Mihoko","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhisa","family":"Ohgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Ashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyasu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimpei","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Dei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Uesaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teiichi","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"3223_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics 2024. Cancer J Clin. 2024;74:12\u201349.","journal-title":"Cancer J Clin"},{"key":"3223_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreatic cancer: A review. JAMA. 2021;326:851\u201362.","journal-title":"JAMA"},{"key":"3223_CR3","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"},{"key":"3223_CR4","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med"},{"key":"3223_CR5","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","volume":"5","author":"JE Murphy","year":"2019","unstructured":"Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, et al. Total neoadjuvant therapy with FOLFIRINOX in combination with Losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: A phase 2 clinical trial. JAMA Oncol. 2019;5:1020\u20137.","journal-title":"JAMA Oncol"},{"key":"3223_CR6","doi-asserted-by":"crossref","unstructured":"Ushida Y, Inoue Y, Oba A, Mie T, Ito H, Ono Y, et al. Optimizing indications for conversion surgery based on analysis of 454 consecutive Japanese patients with unresectable pancreatic cancer who received modified FOLFIRINOX or gemcitabine plus nab-paclitaxel: A single-center retrospective study. Ann Surg Oncol; 2022.","DOI":"10.1245\/s10434-022-11503-6"},{"key":"3223_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1245\/s10434-014-3898-9","volume":"22","author":"L Marthey","year":"2015","unstructured":"Marthey L, Sa-Cunha A, Blanc JF, Gauthier M, Cueff A, Francois E, et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Ann Surg Oncol. 2015;22:295\u2013301.","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 3","key":"3223_CR8","doi-asserted-by":"publisher","first-page":"S1212","DOI":"10.1245\/s10434-015-4851-2","volume":"22","author":"U Nitsche","year":"2015","unstructured":"Nitsche U, Wenzel P, Siveke JT, Braren R, Holzapfel K, Schlitter AM, et al. Resectability after First-Line FOLFIRINOX in initially unresectable locally advanced pancreatic cancer: A Single-Center experience. Ann Surg Oncol. 2015;22(Suppl 3):S1212\u20131220.","journal-title":"Ann Surg Oncol"},{"key":"3223_CR9","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1097\/SLA.0000000000003010","volume":"271","author":"P Bachellier","year":"2020","unstructured":"Bachellier P, Addeo P, Faitot F, Nappo G, Dufour P. Pancreatectomy with arterial resection for pancreatic adenocarcinoma: how can it be done safely and with which outcomes? A single institution\u2019s experience with 118 patients. Ann Surg. 2020;271:932\u201340.","journal-title":"Ann Surg"},{"key":"3223_CR10","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.ejso.2019.04.007","volume":"45","author":"VP Groot","year":"2019","unstructured":"Groot VP, Blair AB, Gemenetzis G, Ding D, Burkhart RA, Yu J, et al. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. Eur J Surg Oncology: J Eur Soc Surg Oncol Br Association Surg Oncol. 2019;45:1674\u201383.","journal-title":"Eur J Surg Oncology: J Eur Soc Surg Oncol Br Association Surg Oncol"},{"key":"3223_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/bjs5.46","volume":"2","author":"S Schorn","year":"2018","unstructured":"Schorn S, Demir IE, Samm N, Scheufele F, Calavrezos L, Sargut M, et al. Meta-analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma. BJS Open. 2018;2:52\u201361.","journal-title":"BJS Open"},{"key":"3223_CR12","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1097\/SLA.0000000000003568","volume":"273","author":"BN Blair","year":"2021","unstructured":"Blair BN, Krell AB, Groot RW, Gemenetzis VP G, et al. Management of locally advanced pancreatic cancer: results of an international survey of current practice. Ann Surg. 2021;273:1173\u201381.","journal-title":"Ann Surg"},{"key":"3223_CR13","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1097\/SLA.0000000000002600","volume":"269","author":"T Michelakos","year":"2019","unstructured":"Michelakos T, Pergolini I, Castillo CF, Honselmann KC, Cai L, Deshpande V, et al. Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX. Ann Surg. 2019;269:733\u201340.","journal-title":"Ann Surg"},{"key":"3223_CR14","doi-asserted-by":"crossref","unstructured":"Mataki Y, Kurahara H, Idichi T, Tanoue K, Hozaka Y, Kawasaki Y et al. Clinical benefits of conversion surgery for unresectable pancreatic ductal adenocarcinoma: A Single-Institution, retrospective analysis. Cancer (Basel). 2021;13(5):1057.","DOI":"10.3390\/cancers13051057"},{"key":"3223_CR15","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.surg.2017.04.023","volume":"162","author":"S Yamada","year":"2017","unstructured":"Yamada S, Fujii T, Takami H, Hayashi M, Iwata N, Kanda M, et al. Evaluation and proposal of novel resectability criteria for pancreatic cancer established by the Japan pancreas society. Surgery. 2017;162:784\u201391.","journal-title":"Surgery"},{"key":"3223_CR16","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma.version 1.2024. https:\/\/www.nccn.org\/login?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf.Accessed 1 February 2024."},{"key":"3223_CR17","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1111\/cas.12501","volume":"105","author":"T Okusaka","year":"2014","unstructured":"Okusaka T, Ikeda M, Fukutomi A, Ioka T, Furuse J, Ohkawa S, et al. Phase II study of FOLFIRINOX for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Sci. 2014;105:1321\u20136.","journal-title":"Cancer Sci"},{"key":"3223_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","volume":"250","author":"PA Clavien","year":"2009","unstructured":"Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187\u201396.","journal-title":"Ann Surg"},{"key":"3223_CR19","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.surg.2016.11.014","volume":"161","author":"C Bassi","year":"2017","unstructured":"Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. 2016 update of the international study group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161:584\u201391.","journal-title":"Surgery"},{"key":"3223_CR20","doi-asserted-by":"crossref","unstructured":"Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B et al. (1992) Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Archives of Surgery (Chicago, Ill.: 1960) 127:1335\u20131339.","DOI":"10.1001\/archsurg.1992.01420110083017"},{"key":"3223_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: A phase 3, open-label, randomized, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248\u201357.","journal-title":"Lancet"},{"key":"3223_CR22","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"3223_CR23","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00280-020-04047-7","volume":"85","author":"M Reni","year":"2020","unstructured":"Reni M, Peretti U, Zanon S, Macchini M, Balzano G, Mazza E, et al. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma. Cancer Chemother Pharmacol. 2020;85:641\u201350.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3223_CR24","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.pan.2023.06.005","volume":"23","author":"A Oba","year":"2023","unstructured":"Oba A, Del Chiaro M, Fujii T, Okano K, Stoop TF, Wu YHA, et al. Conversion surgery for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the international association of pancreatology (IAP) & Japan pancreas society (JPS) 2022. Pancreatology. 2023;23:712\u201320.","journal-title":"Pancreatology"},{"key":"3223_CR25","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","volume":"29","author":"DD Von Hoff","year":"2011","unstructured":"Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I\/II trial. J Clin Oncol. 2011;29:4548\u201354.","journal-title":"J Clin Oncol"},{"key":"3223_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/bjs\/znab229","volume":"109","author":"W Lee","year":"2021","unstructured":"Lee W, Oh M, Kim JS, Park Y, Kwon JW, Jun E, et al. Metabolic activity by FDG-PET\/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival. Br J Surg. 2021;109:61\u201370.","journal-title":"Br J Surg"},{"key":"3223_CR27","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ejso.2017.03.015","volume":"43","author":"H Akita","year":"2017","unstructured":"Akita H, Takahashi H, Ohigashi H, Tomokuni A, Kobayashi S, Sugimura K, et al. FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Eur J Surg Oncology: J Eur Soc Surg Oncol Br Association Surg Oncol. 2017;43:1061\u20137.","journal-title":"Eur J Surg Oncology: J Eur Soc Surg Oncol Br Association Surg Oncol"},{"key":"3223_CR28","doi-asserted-by":"publisher","first-page":"7759","DOI":"10.1245\/s10434-021-10175-y","volume":"28","author":"A Chopra","year":"2021","unstructured":"Chopra A, Zenati M, Hogg ME, Zeh HJ 3rd, Bartlett DL, Bahary N, et al. Impact of neoadjuvant therapy on survival following Margin-Positive resection for pancreatic cancer. Ann Surg Oncol. 2021;28:7759\u201369.","journal-title":"Ann Surg Oncol"},{"key":"3223_CR29","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1158\/0008-5472.CAN-13-2050","volume":"74","author":"RE Stopczynski","year":"2014","unstructured":"Stopczynski RE, Normolle DP, Hartman DJ, Ying H, DeBerry JJ, Bielefeldt K, et al. Neuroplastic changes occur early in the development of pancreatic ductal adenocarcinoma. Cancer Res. 2014;74:1718\u201327.","journal-title":"Cancer Res"},{"key":"3223_CR30","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ctrv.2017.03.003","volume":"55","author":"S Schorn","year":"2017","unstructured":"Schorn S, Demir IE, Reyes CM, Saricaoglu C, Samm N, Schirren R, et al. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis. Cancer Treat Rev. 2017;55:96\u2013106.","journal-title":"Cancer Treat Rev"},{"key":"3223_CR31","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/SLA.0000000000004464","volume":"276","author":"S Crippa","year":"2022","unstructured":"Crippa S, Pergolini I, Javed AA, Honselmann KC, Weiss MJ, Di Salvo F, et al. Implications of perineural invasion on disease recurrence and survival after pancreatectomy for pancreatic head ductal adenocarcinoma. Ann Surg. 2022;276:378\u201385.","journal-title":"Ann Surg"},{"key":"3223_CR32","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/SLA.0000000000005666","volume":"278","author":"LWF Seelen","year":"2023","unstructured":"Seelen LWF, van Floortje A, Brada LJH, Groot VP, Daamen LA, Walma MS, et al. Early recurrence after resection of locally advanced pancreatic cancer following induction therapy: an international multicenter study. Ann Surg. 2023;278:118\u201326.","journal-title":"Ann Surg"},{"key":"3223_CR33","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/SLA.0000000000002753","volume":"270","author":"G Gemenetzis","year":"2019","unstructured":"Gemenetzis G, Groot VP, Blair AB, Laheru DA, Zheng L, Narang AK, et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg. 2019;270:340\u20137.","journal-title":"Ann Surg"},{"key":"3223_CR34","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1245\/s10434-014-4225-1","volume":"22","author":"M Blazer","year":"2015","unstructured":"Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2015;22:1153\u20139.","journal-title":"Ann Surg Oncol"},{"key":"3223_CR35","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1007\/s00595-024-02877-z","volume":"54","author":"T Sakamoto","year":"2024","unstructured":"Sakamoto T, Kishino M, Murakami Y, Miyatani K, Hanaki T, Shishido Y, et al. The cachexia index is a prognostic factor for patients with recurrent pancreatic cancer. Surg Today. 2024;54:1498\u2013504.","journal-title":"Surg Today"},{"key":"3223_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/1457496920911807","volume":"109","author":"B Kurlinkus","year":"2020","unstructured":"Kurlinkus B, Ahola R, Zwart E, Halimi A, Yilmaz BS, Ceyhan GO, et al. In the era of the Leeds protocol: A systematic review and A Meta-Analysis on the effect of resection margins on survival among pancreatic ductal adenocarcinoma patients. Scand J Surg. 2020;109:11\u20137.","journal-title":"Scand J Surg"}],"container-title":["Surgery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-025-03223-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00595-025-03223-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-025-03223-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:57:05Z","timestamp":1782395825000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00595-025-03223-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3223"],"URL":"https:\/\/doi.org\/10.1007\/s00595-025-03223-7","relation":{},"ISSN":["0941-1291","1436-2813"],"issn-type":[{"value":"0941-1291","type":"print"},{"value":"1436-2813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest in association with the present study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval of the research protocol by an institutional review board: This study had a retrospective design and was approved by the Human Research Review Committee of the Shizuoka Cancer Center (J2023-71-2023-1-3). Patient consent for participation was obtained using an opt-out method. This study did not include data from other sources.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patient consent for participation was obtained through an opt-out method.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This study did not include material from other sources.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal studies"}}]}}